Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma
NCT06048250Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mezigdomide in multiple myeloma (MM), sponsored by City of Hope. Primary endpoint: Incidence of adverse events up to 2 years. Started Apr 2024; status: recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06048250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048250.